Continuous monitoring of the number needed to harm (created 2006-09-02).

The continuing review of clinical trials has to address "good news" issues. Does one arm of the study show substantially better efficacy? Does one arm of the study have a significantly better safety profile? There are rigorous and well accepted approaches for determining partway through a clinical trial whether one arm has a greater proportion of cured patients or a smaller proportion of harmed patients.

This webpage was originally published at the StATS website, which is currently unavailable. There is a dispute about the ownership of these pages, so I am only able to include a brief excerpt from this page.

This work is licensed under a Creative Commons Attribution 3.0 United States License. This page was written by Steve Simon and was last modified on 2008-11-10. Need more information? I have a page with general help resources. You can also browse for pages similar to this one at Category: Adverse events in clinical trials.